Related Experiment Video
Updated: Jun 16, 2026
07:59
Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
Published on: May 31, 2024
Optimising in vivo pharmacology studies--Practical PKPD considerations
Johan Gabrielsson1, A Richard Green, Piet H Van der Graaf
1PKPD Section, Drug discovery DMPK & BAC, CVGI, AstraZeneca R&D Mölndal, S-43183 Mölndal, Sweden. Johan.Gabrielsson@AstraZeneca.com
Journal of Pharmacological and Toxicological Methods
|February 16, 2010
Summary
Improving in vivo studies requires integrating pharmacokinetic (PK) and pharmacodynamic (PD) data. This quantitative pharmacology approach enhances understanding of drug effects and safety profiles, optimizing experimental design for better results.
Area of Science:
- Pharmacology
- Drug Development
- Preclinical Research
Background:
- Current methods for assessing drug properties are inefficient, relying heavily on animal studies.
- There's a critical need to improve the understanding of relationships between pharmacokinetics (PK), target actions, and safety.
- Optimizing in vivo studies is essential for maximizing data value and resource utilization.
Purpose of the Study:
- To advocate for an integrative approach in designing and analyzing in vivo pharmacodynamic (PD) studies.
- To address experimental design issues for maximizing information on target engagement.
- To promote quantitative pharmacology (PKPD) for clarifying drug properties and systemic exposure.
Main Methods:
- Presentation of in vivo pharmacological case studies to illustrate experimental design principles.
- Discussion of administration parameters (rate, extent, mode) and their pharmacological impact.
- Examination of temporal concentration-response differences, plasma protein binding (PPB) effects, and ex vivo PPB measurement.
Main Results:
- Case studies demonstrate the impact of experimental design on PKPD data quality.
- Analysis highlights the consequences of administration methods and temporal dynamics on study outcomes.
- The importance of plasma protein binding in assessing pharmacodynamic properties and safety margins is underscored.
Conclusions:
- Quantitative pharmacology emphasizes concentration-response and response-time relationships.
- PKPD integration is crucial for in vivo scientists to understand drug effects on disease.
- This approach enhances the generation and validation of preclinical PKPD and disease model data.
Related Concept Videos
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).